In plain language
In 122 elective endovascular aneurysm repair (EVAR) cases at one centre, letting the operating surgeon control imaging was linked to lower patient dose area product and shorter fluoroscopy time. Staff dose was not measured, though lower dose-area product (DAP) usually means less scatter for the team.
At a glance
- Type of study
- Original research, Retrospective cohort study
- Who was studied
- Patients, Vascular surgeons, Radiologic technologists
- Size
- n = 122 patients
- Summary based on
- the abstract
What it found
Median dose area product was lower after the switch to operator-controlled imaging than before.
Key figures: 4.9 mGy m(2) (range 1.25-13.3) vs 6.9 mGy m(2) (range 1.91-95.0), p = 0.005
Median screening (fluoroscopy) time fell after operator-controlled imaging was introduced.
Key figures: 20.0 min vs 16.2 min, p = 0.027
Contrast volume did not differ significantly.
Key figures: 100 ml vs 90 ml, p = 0.21
The reduction was particularly seen in the number of higher-dose cases.
Limits to keep in mind
Single-centre retrospective before-after comparison of 122 patients, open to time trends and learning effects. Only patient DAP and screening time were measured, not staff dose.
Related research summaries
- Radiation exposure to operating room personnel and patients during endovascular procedures (2013, Dosimetry measurement study)
- Radiation Exposure To Operating Room Personnel And Patients During Endovascular Procedures (2013, Dosimetry measurement study)
- ICRP Draft - Radiological Protection in Fluoroscopically Guided Procedures (Guideline or consensus statement)
- AAPM Medical Physics Practice Guideline 12.a - Fluoroscopy Dose Management (2022, Guideline or consensus statement)
- Radiation Awareness for EVAR in Hybrid Operating Room: An Instant Operator Risk Chart (2021, Dosimetry measurement study)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.